Symptomatic medication use in multiple sclerosis
- 1 October 2003
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 9 (5) , 458-460
- https://doi.org/10.1191/1352458503ms957oa
Abstract
Multiple sclerosis (MS) is one of the most studied neurological diseases, although scarce attention has been placed on symptomatic therapy. The aim of the study was to evaluate the frequency of medication prescription for the major symptoms related to MS in order to better understand the needs of patients. The study was conducted during an epidemiological survey in the province of G enoa, Italy. O ut of 856 patients with MS in the study area, 665 agreed to participate in a structured interview. Two hundred and forty-nine (37%) subjects, with a mean age of 53 years and a mean Expanded Disability Status Scale (EDSS) score of 5.2, were taking at least one symptomatic medication. Four hundred and sixteen (63%) subjects, with a mean age of 49 years and a mean EDSS score of 4.5, were not using symptomatic therapy. The most commonly treated symptoms were pain (28%), spasticity (27%) and mood disorder (16%), while bladder dysfunction (8%) and fatigue (3%) were less frequently treated with medicatio n. Seventy-seven patients (12%) were taking medicatio ns for reasons not directly related to MS. This cross-sectional study underlines the frequency of medication prescription for symptoms such as spasticity and pain, while other common symptoms, such as bladder dysfunction and fatigue, may perhaps be undertreated. The present findings also underline the need for clinical trials on symptomatic therapies.Keywords
This publication has 9 references indexed in Scilit:
- Symptomatic therapy for underrecognized manifestations of multiple sclerosisNeurology, 2002
- Prescribing for multiple sclerosis patients in general practice: a case-control studyJournal of Clinical Pharmacy & Therapeutics, 2001
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosisThe Lancet, 1998
- Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizensClinical Therapeutics, 1996
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Multiple sclerosis: Symptomatic treatmentZeitschrift für Neurologie, 1996
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993